Keith received his undergraduate degree in Physiology and Biochemistry from the University of Southampton in England, followed by a PhD in Neuropharmacology. Following periods of postdoctoral research at the University of Cambridge, England and Harvard University in Boston, Keith embarked upon a career in neuroscience drug discovery, working initially for Merck, Sharp and Dohme, and then Parke-Davis, at research centers established by both companies in England in the early 1980s. In 1994, he moved to the United States to take up a position as Director of New Product Development with Research Biochemicals International, a small Massachusetts company that specialized in providing innovative neurochemicals for use as research tools by the neuroscience research community. In 1997, RBI was purchased by Sigma-Aldrich Corporation, a major life science and high technology company. From 2000, Keith held leadership positions in a variety of areas within Sigma-Aldrich, including strategic marketing, operations and business development. He is currently Site Director at MilliporeSigma, Natick - a business of Merck KGaA, Darmstadt, Germany -where he oversees the production of a range of bioactive small molecules used in both life science research, and diagnostics and testing.
